Ley Sander, MD, PhD, FRCP, FEAN, UCL Queen Square Institute of Neurology, London, UK, comments on the continuing need for new epilepsy drugs. Current enzyme-inducing antiepileptic medications can have serious side effects and the efficacy of current drugs will reduce the efficacy the more treatment a patients receives. Approximately 20-30% of patients additionally do not benefit from the current armamentarium. Prof. Sander subsequently highlights the need for affordable and efficacious therapies that target the causes of epilepsy instead of the symptoms. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.
Prof. Sander received research grants from UCB Pharma; Received honoraria or consultation fees from Angellini, Eisai and UCB; Participated in a company sponsored speaker’s bureau: Angellini, GW, Zogenix and Eisai.